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Abstract: Sialoadhesin (Sn) is a surface receptor expressed on a subset of macrophages in steady state
conditions. During inflammation and diseases, Sn is highly upregulated on macrophages and blood
monocytes. Therefore, therapies using monoclonal antibodies (mAbs) to target Sn-positive (Sn+) cells
are a potential strategy for targeted treatment. It has been shown that Sn internalizes after binding
with a mAb, though it is not clear whether this is species-specific. In this study, new Sn-specific mAbs
were developed and analyzed for cross-reactivity between species. In addition, the newly developed
mAbs were compared to mAbs used in previous research for their epitope recognition and other
Sn-specific characteristics. Both species-specific and cross-reactive antibodies could be identified.
Furthermore, sialic acid-binding of red blood cells (RBC) could be inhibited with mAbs recognizing
different epitopes and all mAb showed internalization of Sn. The newly developed mAbs can be
used as novel tools for Sn research and further analysis of Sn internalization in different species.
Keywords: sialoadhesin; monoclonal antibody; internalization
1. Introduction
Sialoadhesin (Sn), also known as Siglec-1 or CD169, is a member of the family of sialic acid-binding
immunoglobulin-like lectins (Siglecs) and is exclusively expressed on a subset of resident tissue
macrophages in steady state conditions [1–3]. Sn is the largest Siglec, containing 16 constant domains
and an N-terminal variable domain that is able to recognize sialic acids [4]. Although Sn is conserved
between different species, the amino acid sequence of Sn can vary substantially. Interestingly, the
cytoplasmic tail is poorly conserved in length and amino acid sequence, with only 30% of the amino
acid sequence being identical between human and mouse [3,5–7]. Furthermore, Sn does not contain any
known signalization motif in the cytoplasmic tail, which is in contrast with most other Siglecs [4,5,7].
Sn, as a member of the Siglec family, can bind specifically with sialic acid ligands found on cell
surfaces [8,9]. Therefore, Sn was hypothesized to function as a cell–cell receptor. Sn can indeed bind
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with different cells of the granulocytic lineage in a sialic acid-dependent manner, like bone marrow
cells, neutrophils, and blood leukocytes [4,10,11]. Besides cells of the granulocytic lineage, Sn is able to
bind with red blood cells (RBC) in a sialic acid-dependent manner, resulting in the formation of a rosette
structure when these RBC bind to Sn-expressing macrophages. This was the first identified property of
Sn, as reflected in the initial name for Sn being sheep erythrocyte receptor (SER) [12]. The binding of
RBC to Sn can be blocked by monoclonal antibodies (mAbs) close to the sialic acid-binding domain of
Sn [4,13,14].
Although the exact role of Sn is still unknown, different characteristics of Sn were identified and
gave a better understanding of the potential role of Sn and Sn-positive (Sn+) macrophages. Sn can
be drastically upregulated on macrophages, monocytes, and monocyte-derived dendritic cells (DC)
during conditions of inflammation [1–3,13,15,16]. It was shown that Sn+-macrophages can act as
antigen (Ag) presenting cells after targeting Sn with mAbs cross-linked with Ag. This leads to Ag
presentation and the activation of B-, T-, and invariant natural killer T-cells [16–20]. Some bacteria,
protozoa, and viruses containing sialic acids on their surface can interact with Sn+-macrophages [21,22].
Bacteria Neisseria meningitidis and Campylobacter jejuni and protozoa Trypanosoma cruzi interact with
Sn in a sialic acid-dependent manner and aid the phagocytosis of the pathogen [23–25]. Porcine
reproductive and respiratory syndrome virus (PRRSV) and human immunodeficiency virus type 1
(HIV-1) contain sialic acids on their envelope and are able to interact with Sn+-macrophages and
Sn+-DC respectively [6,26–28]. Interestingly, for all these pathogens, the binding and uptake in the
cell can be inhibited or reduced after addition of anti-Sn mAbs [14,23–25,29]. After the discovery of
sialic acid-dependent internalization of pathogens through Sn, internalization was further studied.
Liposomal nanoparticles were produced with sialic acid on their surface to target Sn and deliver their
cargo, which results in the activation of invariant natural killer T-cells [16,30,31].
Antibody-induced internalization was previously studied for other Siglecs. Anti-CD33 and
anti-CD22 mAbs were also shown to induce internalization and targeting of these Siglecs is
a therapeutic approach to target malignant cells [32,33]. Similar to other Siglecs, internalization of Sn
after mAb triggering was studied and internalization was observed for porcine (pSn), human (hSn),
and murine Sn (mSn) [6,30,34]. MAb-induced internalization of pSn occurs in a clathrin-dependent
manner, after which antibodies are located in early endosomes [35]. The mAb-induced internalization
of pSn was documented by different research groups using two different mAbs, 41D3 and 1F1, but no
direct comparison was done. Both mAbs are able to inhibit RBC binding, indicating that they both
recognize a region close to the sialic acid-binding domain [36,37]. However, it is not clear if these mAbs
recognize the same epitope. Previous research of other surface proteins showed that internalization is
different for mAbs recognizing a different epitope [38,39]. Also for Sn, it might be possible that the
epitope recognition of the mAb is important for the internalization of Sn. Previous studies analyzed the
importance of the cytoplasmic tail of Sn. Sn-mutants without a cytoplasmic tail resulted in a decreased
infection of virus that utilizes Sn as an internalization receptor, which can be due to a lower expression
of the Sn-mutant or a loss of internalization capacity [40]. Similarly, adding a di-aromatic motif in the
cytoplasmic tail of Sn resulted in internalization of HIV-1, while binding of HIV-1 to the wild-type
Sn only results in invagination of the Sn–HIV-1 complex [34]. Yet, such motif has not been identified
and since the cytoplasmic tail of Sn is poorly conserved between species, a different mechanism of
mAb-induced internalization might be possible. This is preferentially analyzed using cross-reactive
mAbs, which are not available yet, to rule out antibody-specific effects [7,34,40].
In this study, we developed new anti-Sn mAbs to obtain a broader range of available anti-Sn
mAbs, and possibly species cross-reactive mAbs. In addition, we aimed to further investigate the
internalization of mSn, where sometimes conflicting results are described regarding its capacity to
internalize [30,41]. We compared the newly developed anti-Sn mAbs with anti-Sn mAbs already
described in previous research. For hSn, the most commonly used mAb is 7D2, produced by
immunizing mice with a soluble and truncated form of hSn that only contains the first four N-terminal
domains of hSn [3]. MAb 3D6 is an anti-mSn mAb, produced by immunizing rats with purified
Antibodies 2016, 5, 7 3 of 18
mSn [10]. MAb 41D3, an anti-pSn mAb, was developed by immunizing mice with porcine alveolar
macrophages [42]. Most research regarding the internalization of Sn was performed with these mAbs,
however contradicting results were observed by using mAb 3D6 and 7D2 to induce mSn or hSn
internalization, respectively [30,41]. In this study, all experiments were performed in Chinese hamster
ovary cells (CHO) cells expressing a recombinant Sn (Sn+-CHO) to overcome differences that might
arise from the use of primary cells expressing Sn and the different species origin of the cells. We also
evaluated the cross-reactivity of the mAbs and analyzed their functionality using immunofluorescence
staining and Western blot analysis, and the mAbs were clustered according to the epitopes they
recognize. Finally the capacity of the mAbs to inhibit the sialic acid-dependent binding and the
capacity to induce internalization of Sn was evaluated.
2. Results and Discussion
2.1. Development and Characterization of mAbs
A first immunization was done in separate rats using two different conserved peptides from the
6th extracellular domain of hSn, pSn, and mSn. This resulted in 17 different hybridomas that were
screened using peptide-based and cell-based enzyme-linked immunosorbent assay (ELISA). All the
mAbs were able to recognize the conserved peptides used for initial immunization. However, none
of them reacted with Sn+-CHO cells, suggesting that these linear epitopes were not accessible in the
native protein (data not shown).
Since this first approach was not successful, a second immunization was set up in which,
respectively, mice were immunized with cells expressing hSn and rats with the extracellular domain of
mSn fused to a murine IgG2a Fc backbone. Obtained anti-hSn hybridomas were screened by ELISA
for recognition of hSn, while for the anti-mSn hybridomas, a negative selection was first performed to
eliminate hybridomas that recognize the murine IgG2a Fc backbone, followed by a positive selection
for the recognition of mSn. This resulted in a selection of 14 hybridoma clones recognizing recombinant
hSn and two hybridoma clones recognizing recombinant mSn. Moreover, ELISA results showed that
nine of these anti-hSn hybridoma cross-reacted with pSn but no cross-reactivity was observed with
the mSn clones (Table 1). All mAbs had an IgG1 kappa isotype, except 26B2 and 17B12, which had
an IgG2b kappa isotype (Table 1).
Further screening of the different mAbs was performed using microscopic analysis and flow
cytometry. For immunofluorescent staining, mAbs were added to Sn+-CHO cells and wild-type
CHO cells were used as the negative control. The newly developed mAbs were compared to the
reference mAbs 7D2, 3D6 and 41D3, which were previously developed by other groups and have been
extensively used [3,10,42]. Based on immunofluorescent staining, only seven of the 14 ELISA-positive
clones resulted in a staining of hSn+-CHO cells and gave no background staining on wild type
CHO cells. Only five of these mAbs (12A4, 24B5, 25B7, 30A6, and 30E6) also stained pSn, yet with
a lower intensity (Figure 1A). For the anti-mSn mAbs only mAb SySy94 resulted in a clear staining
of mSn+-CHO cells. MAb SySy304 also stained mSn+-CHO cells, yet the staining was less clear and
limited to the bottom of the cell that makes contact with the plate (Figure 1B). All reference mAbs gave
a clear surface staining (Figure 1C).
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Table 1. Overview of developed hybridoma clones. A selection was made by screening the hybridomas
with enzyme-linked immunosorbent assay (ELISA) for recognition of human sialoadhesin-positive
(hSn+), porcine sialoadhesin-positive (pSn+), and murine sialoadhesin-positive (mSn+) cells. * Indicated





10H1 * Yes No No mIgG1 kappa
12A4 * Yes Yes No mIgG1 kappa
14E5 Yes No No mIgG1 kappa
17B12 Yes No No mIgG2b kappa
21B7 Yes Yes No mIgG1 kappa
22F3 Yes No No mIgG1 kappa
24B5 * Yes Yes No mIgG1 kappa
24F6 Yes Yes No mIgG1 kappa
25B7 * Yes Yes No mIgG1 kappa
25F3 Yes Yes No mIgG1 kappa
26B2 Yes Yes No mIgG2b kappa
26G1 Yes No No mIgG1 kappa
30A6 * Yes Yes No mIgG1 kappa
30E6 * Yes Yes No mIgG1 kappa
SySy94 No No Yes rIgG1 kappa
SySy304 No No Yes rIgG1 kappa
The capacity of the mAbs to recognize Sn was also analyzed with flow cytometry. Different
concentrations of mAbs were added to the cells to give an indication of the relative binding capacity
of the newly developed mAbs compared to the reference mAbs. All seven anti-hSn mAbs were able
to recognize cell surface-expressed hSn. Staining with mAbs 12A4, 24B5, 25B7, and 30A6 resulted
in a higher fluorescent signal at lower mAb-concentrations compared to the reference mAb 7D2.
Only mAb 14E5 had a lower fluorescent signal relative to all other anti-hSn mAbs (Figure 2A).
For pSn, the same five mAbs that recognized pSn in previous experiments also recognized pSn using
flow cytometry. MAbs 12A4, 30A6, and 30E6 gave a stronger signal at a lower mAb concentration
than the reference mAb 41D3 using pSn+-CHO cells as a target; however, this difference was not
significant. MAbs 10H1 and 14E5, only recognizing hSn in previous experiments, resulted in no or
very low fluorescent signals when staining pSn+-CHO cells (Figure 2B). For murine Sn, only mAb
SySy94 recognized mSn, mAb SySy304 gave no staining even at the highest mAb concentration
(Figure 2C). Several of the new mAbs were able to recognize Sn at a lower mAb concentration,
suggesting a higher relative binding capacity compared to the reference mAb, especially for mAb
SySy94, which is significantly different compared to mAb 3D6. Based on these data, a selection of
mAbs was made for further experiments, which is indicated in Table 1 with an asterisk.
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Figure 1. Microscopic analysis of surface staining of sialoadhesin (Sn) on CHO cells. Monoclonal 
antibodies (mAbs) were added to fixed Sn+ CHO cells to analyze the recognition of surface Sn. 
Secondary Alexa Fluor 488-labeled antibodies were added to bind with the mAbs (green), nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI) (blue). Wild-type CHO cells were used as 
control cells. (A) All anti-hSn mAbs were tested against hSn+-CHO and pSn+-CHO; (B) anti-mSn 
mAbs were used to stain mSn+-CHO; (C) reference mAbs 7D2, 3D6, and 41D3 were analyzed for 
recognition of hSn+-, pSn+-, and mSn+-CHO cells, respectively. 
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Figure 2. Flow cytometric analysis of mAbs binding to Sn+-CHO cells. Different concentrations of 
mAbs were added to CHO cells expressing (A) hSn; (B) pSn; and (C) mSn, followed by secondary 
fluorescently-labeled Ab. Surface staining was measured only on living cells by excluding dead cells 
using propidium iodide (PI). Data represents the relative mean fluorescence intensity (MFI) and 
standard error of the mean of three independent repeats. 
2.2. MAb Recognition of Sn on Western Blot 
Anti-Sn reference mAbs were used in previous research to recognize Sn on Western blot. All 
mAbs 7D2, 3D6, and 41D3 were previously shown to recognize Sn in both reducing and 
non-reducing conditions [3,6,43]. The newly developed mAbs were analyzed for their ability to 
recognize Sn on Western blot under reducing and non-reducing conditions. CHO cells with and 
without Sn were lysed and the Western blot membranes were stained with the different newly 
developed mAbs, as shown in Figure 3. Wild-type CHO cells were used as negative control where 
no Sn staining was visible in both reducing and non-reducing conditions. HSn was detected only in 
non-reducing conditions by all newly developed mAbs except for mAb 10H1, which also recognized 
Sn in reducing conditions. For mAbs 10H1, 24B5, 30A6, and 30E6, a dimer of Sn was also observed. 
MAbs 30A6 and 30E6 were the only newly developed mAbs with less recognition of hSn in Western 
blot analysis. In addition, non-specific signal was also observed using these mAb, indicating that 
Figure 2. Flow cytometric analysis of mAbs binding to Sn+-CHO cells. Different concentrations of
mAbs were added to CHO cells expressing (A) hSn; (B) pSn; and (C) mSn, followed by secondary
fluorescently-labeled Ab. Surface staining was measured only on living cells by excluding dead
cells using propidium iodide (PI). Data represents the relative mean fluorescence intensity (MFI) and
standard error of the ean of three independent repeats.
2.2. MAb Recognition of Sn on Western Blot
Anti-Sn reference mAbs were used in previous research to recognize Sn on Western blot. All mAbs
7D2, 3D6, and 41D3 were previously shown to recognize Sn in both reducing and non-reducing
conditions [3,6,43]. The newly developed mAbs were analyzed for their ability to recognize Sn on
Western blot under reducing and non-reducing conditions. CHO cells with and without Sn were lysed
and the Western blot membranes were stained with the different newly developed mAbs, as shown
in Figure 3. Wild-type CHO cells were used as negative control where no Sn staining was visible in
both reducing and non-reducing conditions. HSn was detected only in non-reducing conditions by
all newly developed mAbs except for mAb 10H1, which also recognized Sn in reducing conditions.
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For mAbs 10H1, 24B5, 30A6, and 30E6, a dimer of Sn was also observed. MAbs 30A6 and 30E6 were
the only newly developed mAbs with less recognition of hSn in Western blot analysis. In addition,
non-specific signal was also observed using these mAb, indicating that these mAbs are not suitable
for Western blotting. Interestingly, none of the cross-reactive mAbs were able to recognize pSn using
Western blot analysis, except for mAb 12A4 with a low intensity. MAb SySy94 was able to recognize
mSn only in non-reducing conditions, as a monomer and dimer. These results show that all mAbs,
except for mAb 10H1, recognize an epitope of Sn only found in non-reducing conditions and not in
reducing conditions. For further research using Western blot techniques, mAb SySy94 can be used to
detect mSn and mAb 25B7 is the best mAb for hSn recognition but not for pSn.
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Figure 3. Western blot analysis of the different mAbs. Lysates of CHO, hSn+-CHO, pSn+-CHO, and 
mSn+-CHO were run under non-reducing (-β mercaptoethanol (ME)) and reducing (+β ME) 
conditions. The newly developed mAbs were added to the blots followed by an anti-mouse or 
anti-rat horseradish peroxidase (HRP)-labeled secondary antibody. Sn monomers and dimers are 
indicated with one line and two lines respectively. The arrow indicates 220 kDa. 
2.3. Clustering of the Anti-Sn mAb Based on a Competitive Binding Assay 
Clustering of the different mAbs based on a mAb-competition assay was previously shown for 
other proteins using a combination of biotinylated and non-biotinylated mAbs [44,45]. An excess of 
unbiotinylated mAbs was added to the cells and were allowed to bind to surface-expressed Sn for 60 
min at 37 °C. Afterwards, biotinylated-mAbs were added and their capacity to bind was evaluated 
Figure 3. Western blot analysis of the different mAbs. Lysates of , hSn+-CHO, pSn+-CHO, and
mSn+-CHO were run under non-reducing (-β mercaptoethanol (ME)) and reducing (+β ME) conditions.
The newly develop d mAbs were ad ed to the blots followed by an anti-mouse or anti-rat horseradish
peroxidase (HRP)-labeled secondary antibody. Sn monomers an dimers are indicated with one line
and two lines respectively. The arrow indicates 220 kDa.
2.3. Clustering of the Anti-Sn mAb Based on a Competitive Binding Assay
Clustering of the different mAbs based on a mAb-competition assay was previously shown for
other proteins using a combination of biotinylated and non-biotinylated mAbs [44,45]. An excess of
unbiotinylated m bs as added to the cells and were allowed to bind to surface-expressed Sn for
60 min at 37 ˝C. Afterwards, biotinylated-mAbs were added and their capacity to bind was evaluated
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with flow cytometry using fluorescein isothiocyanate (FITC)-labeled streptavidin. If the epitopes
recognized by both mAbs are the same or in close proximity so that steric hindrance may occur,
biotinylated-mAbs will not bind to Sn or will do so less effectively. In this case, no fluorescent signal or
a lower one will be detected. However, if the biotinylated-mAbs interact with another epitope, a clear
fluorescent signal will be detected. As a positive control, the same mAb is used both unbiotinylated
and biotinylated and the low fluorescence signal detected in this setting is used as the reference signal
that indicates that the mAbs bind the same epitope or are in very close proximity.
MAb 30E6 was chosen as the first mAb to be biotinylated since it recognizes both hSn and pSn.
These experiments (Figure 4A,B) suggest that all mAbs recognizing both hSn and pSn (12A4, 24B5,
25B7, 30A6, and 30E6) bind the same epitope on Sn. However, the hSn-specific mAbs 10H1 and 7D2,
and the pSn-specific mAb 41D3, recognized another epitope (p < 0.05). Based on these results, mAb
10H1 was biotinylated to compare the epitope with mAb 7D2. All mAbs had a high fluorescent signal
except for mAb 10H1, suggesting that mAb 10H1 recognizes a different epitope compared to the
other newly developed anti-hSn mAbs and the reference mAb 7D2 (p < 0.05) (Figure 4C). Finally,
mAb SySy94 was biotinylated to compare the epitope with mAb 3D6. The fluorescent signals showed
that the epitope for mAbs SySy94 and 3D6 is significantly different (Figure 4D). An overview of the
clustering of the different mAbs is given in Table 2.
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as added to Sn+-cells. After 60 min of incubation, biotinylated-mAbs were added and unbound
mAbs were removed after 60 min. Fluorescently-labeled streptavidin was added to stain only the
bound biotinylated-mAbs. Dead cells were excluded using PI. A high fluorescent signal indicated the
mAb had a different epitope than the biotinylated-mAb. MAb 30E6 was biotinylated and added to ( )
hSn -CHO and ( ) pSn+-CHO. Biotinylated mAbs 10 1 and SySy94 ere added to ( ) hSn - and
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Table 2. Clustering of the different mAb based on the site on Sn they bind. Each column indicates the
mAbs that are grouped in the same cluster for, respectively, hSn, pSn, and mSn.
hSn pSn mSn
Cluster 1 Cluster 2 Cluster 3 Cluster 1 Cluster 4 Cluster 5 Cluster 6





2.4. Capacity of mAbs to Block the Sialic Acid-Binding of Sn
One of the first discovered properties of Sn is the ability to interact with sialic acids on red
blood cell (RBC) resulting in the formation of rosettes, a feature that is conserved in all species
studied [4,13,14]. The binding of RBC to Sn can be blocked using mAbs but only if the mAb binds
to or is in close proximity to the sialic acid-binding domain of Sn, which is located in the N-terminal
variable domain [13,46]. The reference mAbs 7D2, 3D6, and 41D3 were all able to interfere with RBC
binding, as documented in previous research, suggesting that they all bind to or are in close proximity
to the sialic acid-binding domain of Sn [3,10,14,42]. Yet, it has also been shown that mAbs can interfere
with binding of RBC to Sn even when recognizing different epitopes; this was illustrated for mAbs
SER-4 and 3D6, both recognizing mSn [10]. In this study, different concentrations of mAbs were added
to Sn+-cells to allow binding with Sn before adding human RBC. Unbound RBC were removed and
rosette formation was analyzed using light microscopy. A cell with at least four bound RBC was
considered a positive cell [14].
All anti-hSn mAbs were able to inhibit the RBC binding on hSn+-cells in a dose-dependent manner
(Figure 5A). The highest concentration used almost entirely inhibited RBC binding to hSn. Our results
suggest that a higher concentration of mAb 7D2 is needed for the same inhibition of the RBC binding
compared to the newly developed mAbs. MAb 30A6 seemed to inhibit the RBC binding better
compared to the other anti-hSn mAbs, since the inhibition of this binding already occurred at low mAb
concentrations (Figure 5A). For pSn, all mAbs could inhibit RBC binding to pSn in a dose-dependent
manner. MAbs 12A4 and 30A6 inhibited the RBC binding already at low concentrations compared to
the other mAbs but with no significant difference (Figure 5B). Anti-mSn mAbs SySy94 and 3D6 reacted
similarly to the inhibition of RBC binding in a dose-dependent manner (Figure 5C). To conclude, these
results suggest that the newly developed, different mAbs recognize different epitopes and could all
bind to the sialic acid-binding domain of Sn or in close vicinity. For research where blocking of the
sialic acid-binding domain is important, such as preventing binding of sialylated pathogens, mAb
30A6 could be used for both hSn and pSn at already low concentrations.
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Figure 5. Analysis of red blood cell (RBC) binding inhibition on Sn+-cells. (A) hSn+-; (B) pSn+-; and (C) 
mSn+-CHO cells were treated with Vibrio cholerae neuraminidase to remove sialic acids on the cell 
surface before adding different concentrations of mAbs. MAbs were able to bind Sn and prevent RBC 
binding before RBC were added. Unbound RBC were washed away and rosette formation was 
analyzed with light microscopy. Cells were counted to obtain a percentage of positive cells, which 
are cells bound to at least four RBC. Data show the results of three independent repeats with 
standard error of the mean. (D) Representative light microscopic images of RBC binding to Sn+-cells 
in the (1) absence or (2) presence of an anti-Sn mAb that blocks sialic acid binding. Scale bar: 10 µm. 
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Figure 5. Analysis of red blood cell (RBC) binding inhibition on Sn+-cells. (A) hSn+-; (B) pSn+-; and
(C) mSn+-CHO cells were treated with Vibrio cholerae neuraminidase to remove sialic acids on the
cell surface before adding different concentrations of mAbs. MAbs were able to bind Sn and prevent
RBC binding before RBC were added. Unbound RBC were washed away and rosette formation was
analyzed with light microscopy. Cells were counted to obtain a percentage of positive cells, which are
cells bound to at least four RBC. Data show the results of three independent repeats with standard
error of the mean. (D) Representative light microscopic images of RBC binding to Sn+-cells in the (1)
absence or (2) presence of an anti-Sn mAb that blocks sialic acid binding. Scale bar: 10 µm.
2.5. Capacity of mAbs to Induce Internalization of hSn, pSn, and mSn
Although Sn was originally described as a receptor only involved in cell–cell interactions, Sn is
capable of internalization after binding of specific ligands, such as anti-Sn mAb. This feature was first
observed with pSn, which internalizes upon binding of mAb 41D3 [6]. Another mAb was also shown to
induce internalization of pSn, however no direct comparison was made between these mAbs [6,18,35].
Similar to pSn, hSn and mSn were also shown to internalize after mAb triggering; however, some
contradicting results were described [26,30,34,40,41]. Therefore, the newly developed mAbs were
evaluated for their capacity to induce Sn internalization and compared to the reference mAbs.
Internalization of Sn was studied by immunofluorescent stainings in combination with confocal
microscopy and flow cytometry. Using confocal fluorescence microscopy, a clear surface staining was
visible at time 0 for all mAbs. When internalization was allowed for 60 min, intracellular vesicles were
observed for hSn, pSn, and mSn using all different mAbs (Figure 6; Figure S1). These results show that
the newly developed mAbs and reference mAbs were able to induce internalization after binding with
Sn. Although some contradicting results have been described for mSn internalization using mAb 3D6,
our results indicate that mAb 3D6 is able to induce internalization of mSn.
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Figure 6. Internalization of Sn induced by different Sn-specific mAbs. (A) Newly developed mAbs and
(B) reference mAbs were added to the cells for 60 min at 4 ˝C to allow only surface staining. Cells where
then fixed (0 min) or were brought to 37 ˝C to induce internalization (60 min). Cells were permeabilized
so internalized vesicles could be observed. Secondary Alexa Fluor 488-labeled antibodies were added
to the cells (green) and DAPI was used to stain the nuclei (blue).
Internalization of Sn was also analyzed with flow cytometry. MAbs were added to the
cells at 4 ˝C to allow surface staining before internalization was induced by shifting the cells to
37 ˝C. Fluorescently-labeled antibodies were added to non-permeabilized cells to stain only cell
surface-expressed Sn. Upon internalization, less fluorescent signal was observed. Furthermore, the
results showed that not all surface Sn is internalized into the cells. This was also previously illustrated
for mAbs 7D2 and 41D3 resulting, respectively, in 68% and 60% Sn remaining on the surface [34,35].
All mAbs induced internalization and approximately 50% and 60% of hSn and pSn, respectively,
remained on the cell surface and no significant differences were observed between mAbs tested.
Interestingly, a small difference in internalization was observed for the cross-reactive mAbs less hSn
remained on the surface in contrast to pSn (Figure 7A,B). This suggests that, although the mAbs are
cross-reactive, binding to hSn might be more efficient. For mSn, 3D6 induced a higher reduction of Sn
surface expression compared to SySy94 (p < 0.05) (Figure 7C). This difference can be explained by the
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difference in relative binding capacity as previously observed for these mAbs. Another explanation
could be that mSn has multiple conformations on the cell surface that are differentially recognized by
Sn-specific mAbs, and that do not internalize with the same efficiency after mAb binding. Also, not
all Sn+-cells show internalization upon mAb binding, as previously shown [35]. In addition, binding
of the mAb to different epitopes could also result in different characteristics of Sn-internalization.
Such differences have been described for other surface receptors using mAb that recognize different
epitopes of the same receptor [38,39]. Clearly, more research is needed to analyze the mAb-induced
internalization of Sn in more detail.
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Figure 7. Flow cytometric analysis of internalization capacity of different mAbs on Sn+-CHO cells. The
cells were incubated with different mAbs to allow only binding to surface-expressed (A) hSn; (B) pSn;
and (C) mSn. Afterwards the cells were shifted to 37 ˝C during 60 min to induce internalization of Sn.
Secondary fluorescently-labeled antibodies were added to the cells, staining only remaining surface-Sn.
Only viable cells were analyzed with flow cytometry using PI staining. Data represent the mean and
standard error of the mean of three independent repeats. Relative internalization was calculated by
comparing the fluorescent signal to that of cells without internalization.
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3. Materials and Methods
3.1. Ethical Statement
The animal experiments were evaluated and authorized by the Ethical Committee of the Faculty
of Veterinary Medicine of Ghent University (Permit number EC2010/161).
3.2. Production of hybridoma cells and screening
Alignment of the amino acid sequence of Sn from different species revealed two peptides
that are conserved in hSn, pSn, and mSn, but not in rat Sn (520AEVVEGQAVTLSCRS534 and
559SSLLLPAASSTDAGSY574). These peptides were synthesized, linked to the immune carrier keyhole
limpet hemocyanin (KLH), and used for immunization of rats. The developed hybridomas were
screened by ELISA for the recognition of the peptides and surface-expressed Sn.
An antibody against hSn was made by immunizing mice with Mouse Embryonic Fibroblast cells
that were transduced with full-length hSn using a retrovirus system. The hybridomas were screened
by ELISA of their supernatant against recombinant hSn with a C-terminal His-tag (R&D Systems,
Oxon, UK) and CHO-K1 cells stably expressing hSn.
Antibodies against mSn were raised by immunization of rats with recombinant mSn with
C-terminal murine IgG2a (R&D Systems). The hybridoma supernatants were screened by ELISA
against recombinant murine Sn and murine IgG2a to exclude hybridomas that produce antibodies
against the Fc-part of recombinant mSn, which has an IgG2a isotype.
MAbs were produced and purified by culturing the hybridoma cell lines in standard Falcon
T-flasks. To scale up the production, Triple Falcons were used. The serum used in the culture medium
was first depleted of the bovine immunoglobulins by running it on a protein G affinity column. In some
experiments, serum was replaced by Insulin-Transferrin-Selenium-Ethanolamine supplement (ITS–X;
Life Technologies, Grand Island, NY, USA). Purification of the mAbs from the hybridoma supernatant
was performed on a protein G affinity column using a peristaltic pump.
Isotyping of the different anti-hSn and anti-mSn mAbs was performed using a mouse
Immunoglobulin Isotyping ELISA Kit and rat isotyping kit from BD Biosciences respectively.
Produced mAb were compared to reference mAb, 7D2 (Thermo Scientific, Rockford, IL, USA),
3D6.112 (Antibodies online, Aachen, Germany) and 41D3 [42].
3.3. Cells
CHO-K1 cells, kindly provided by Dr. J. D. Esko (University of California, San Diego, CA, USA),
were transfected with pSn to obtain a stable cell line [47], or transduced using a retroviral system.
These cells were grown in F-12K medium supplemented with 10% heat inactivated fetal bovine serum
(Life Technologies).
3.4. Recognition of Sn and internalization assay
Cells were seeded on a coverslip for 2 h. Primary mAbs, were added to the cells during 60 min
and cells were kept on ice to allow surface staining. Afterwards cells were directly fixed with 4%
paraformaldehyde (PF; Merck, Molsheim, France) or first shifted to 37 ˝C to stimulate internalization
and then fixed. Cells were permeabilized using Triton X-100 (Sigma-Aldrich, Schnelldorf, Germany)
and Alexa Fluor 488-chicken anti-mouse or Alexa Fluor 488-chicken anti-rat (Life Technologies)
secondary antibodies were added to label the primary antibody. Nuclei were stained with DAPI
(Sigma-Aldrich). Confocal images were obtained using Apotome 2 with an Axio Observer inverted
microscope and a Compact Light Source HXP 120C with Filter set 49 and 10 for blue and green
fluorophores respectively (Zeiss) and using a Nikon Eclipse Ti-E inverted microscope attached to
a microlens-enhanced dual spinning disk confocal system (UltraVIEW VoX; PerkinElmer, Zaventem,
Belgium) equipped with 405 and 488 nm diode lasers for excitation of blue and green respectively.
Images were processed using ImageJ software (New York, NY, USA).
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3.5. Flow cytometric analysis
Cells in suspension were kept on ice during the entire experiment in a 96-well plate with V-shaped
bottom. Antibodies were added in different concentrations to the cells and mAbs were allowed to
bind with surface Sn during 60 min at 4 ˝C. Unbound mAbs were washed away and internalization
was induced by shifting the cells to 37 ˝C. Internalization was stopped by cooling the cells to 4 ˝C.
For further processing, cells were kept on ice to prevent internalization. Secondary antibodies, Alexa
Fluor 488-chicken anti-mouse for pSn or Alexa Fluor 647-goat anti-mouse (Life Technologies, Frederick,
MD, USA) for hSn and Alexa Fluor 488-chicken anti-rat for mSn were added to stain remaining
surface mAb-labeled Sn. Cells were gated in a FCS/SSC dot plot to exclude cell debris and dead
cells were excluded using propidium iodide labelling (PI, Sigma-Aldrich, Schnelldorf, Germany).
Cells were analyzed with a FACSCalibur flow cytometer equipped with a blue (λex = 488) and red
diode lasers (λex = 635). The used band pass filter were FL1 (515–545 nm); FL3 (670 long pass) and
FL4 (653–669 nm). Mean fluorescence intensity (MFI) for surface staining was calculated relative to
cells stained without primary mAbs (MFIbackground). The amount of internalization was calculated as
follows: [MFI60 min ´MFIbackground] / [MFI0 min ´MFIbackground] ˆ 100.
3.6. Western blot
Cells were lysed using 2% Triton X-100 in TNE buffer (25 mM Tris-HCl (Sigma-Aldrich), 150 mM
NaCl (VWR, Leuven, Belgium) and 5 mM EDTA (Sigma-Aldrich, Schnelldorf, Germany)) with
Complete protease inhibitor cocktail (Roche, Vilvoorde, Belgium) for 60 min at 37 ˝C as previously
described [35]. Briefly, Laemlli buffer (Bio-Rad, Mitry-Mory, France) was added to lyse cells with or
without β-mercaptoethanol (Sigma-Aldrich) and boiled. Samples were loaded on a Mini-PROTEAN
TGX precast electrophoresis gel (Bio-Rad, Mitry-Mory, France). The samples were transferred onto
an Immobilon-P transfer membrane (Millipore, Molsheim, France). The membrane was blocked with
Tris-buffered saline-Tween 20 before adding 5 µg/mL mAb, followed by a peroxidase-conjugated
anti-mouse or anti-rat secondary antibody (Dako, Glostrup, Denmark and Life Technologies, Frederick,
MD, USA). Chemiluminiscence was measured after 5 min of substrate incubation with SuperSignal
West Pico Chemiluminiscent Substrate (Thermo Scientific, Rockford, IL, USA) using a Genoplex Chemi
camera (VWR, Leuven, Belgium).
3.7. Competitive binding assay
MAbs were biotinylated with EZ-link NHS-SS-biotin (Thermo Scientific, Rockford, IL, USA)
following the manufacturer’s instructions. Cells were kept in a 96-well plate with V-bottom on ice
during the entire experiment. 10 µg/mL unbiotinylated-mAbs were added to the cells and surface
binding of mAb to Sn was allowed. After 60 min, biotinylated-mAbs were added at 5 µg/mL.
Unbound mAbs were washed away before adding fluorescently-labeled streptavidin, FITC for pSn
and mSn, and Alexa Fluor 647 for hSn (Life Technologies, Frederick, MD, USA). Viable cells were
analyzed after PI staining with flow cytometry. MFI was calculated relative against cells incubated
with phosphate-buffered saline (PBS) instead of unbiotinylated-mAbs taking background fluorescence
into account.
3.8. Red blood cell binding assay
RBC binding assay was performed using a previously described protocol [48]. Briefly, Sn+-cells
were treated with 10 mU/mL Vibrio cholerae neuraminidase (Roche, Vilvoorde, Belgium) to remove all
the sialic acids. MAbs were added to the cells, after 60 min human RBC were added to allow mAbs to
bind with hSn, pSn, or mSn and prevent RBC rosetting. As a positive control, no mAbs were added to
the cells. Rosette formation was analyzed using light microscopy and the percentage positive cells,
with at least four bound RBC, was calculated.
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3.9. Statistical analysis
Statistical analysis was performed using a student’s T-test. Significant difference was shown
when the p-value is lower than 0.05.
4. Conclusions
In this study, new anti-Sn mAbs were developed. MAbs cross-reactive with both hSn and pSn
were identified, but not with mSn. The greater amino acid sequence diversity between mSn and hSn
or pSn most likely accounts for this, since there is only 30% amino acid sequence identity between
mSn and hSn [3]. For mSn, a new anti-mSn mAb was developed with better binding properties
compared to the commonly used mAb 3D6. Our results showed that the newly developed mAbs
and the commonly used mAbs, here used as a reference, recognize a different epitope. All mAbs
can inhibit sialic acid-binding, which suggests that these are all reactive with the first, N-terminal
variable domain of Sn. Previous research showed that, depending on the epitope recognized by a mAb,
differences can be observed on the internalization of surface proteins. Here, we observed no major
differences in internalization when using mAbs recognizing different epitopes, suggesting that this
has no major effect on Sn internalization. Further research regarding internalization is needed for
a better understanding of the internalization capacity of Sn and to allow the use of Sn-specific mAbs as
a possible therapy to target Sn+-cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4468/5/1/7.
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